Extract
The acute respiratory distress syndrome (ARDS) remains an intractable problem for intensivists, even with advancements in critical care and mechanical ventilation. Mortality rates in ARDS patients are around 35–45% [1]. However, these mortality numbers represent a conservative estimate of the ARDS healthcare impact, because survivors exhibit staggering rates of morbidity and mortality in the aftermath of their intensive care unit (ICU) stay, including neurocognitive dysfunction that can prohibit the return to activities of daily living [2, 3]. Development of medical therapies that improve both the short- and long-term outcomes of these critically ill patients remain an urgent unmet need.
Abstract
eNAMPT neutralisation may be effective treatment in acute respiratory distress syndrome https://bit.ly/3oaES9c
Acknowledgement
We thank Raymond Langley for his helpful discussions regarding the circulating metabolome in sepsis.
Footnotes
Conflict of interest: J.Y. Lee has nothing to disclose.
Conflict of interest: R.P. Stevens has nothing to disclose.
Conflict of interest: M. Migaud has nothing to disclose.
Conflict of interest: T. Stevens has nothing to disclose.
Support statement: This work was supported in part by HL66299 (T. Stevens), HL60024 (T. Stevens), HL148069 (T. Stevens) and CDA34080151 (J.Y. Lee). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received December 23, 2020.
- Accepted January 17, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org